Evidence map›Paper›PMID 40974379›Full record

ArticleAnnals of hematology2025

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.

Fanghua Ye, Leyuan Wang, Yujie Qian, Wenjun Deng, Yan Yu, Liangchun Yang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fanghua YeDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Leyuan WangDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Yujie QianDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Wenjun DengDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Yan YuDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Liangchun YangDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China. 405010@csu.edu.cn.

Funding

Natural Science Foundation of Hunan Province 2024JJ5598Natural Science Foundation of Hunan Province 2025JJ60564
6 · The paper itself

Abstract

PDGFRB-rearranged acute lymphoblastic leukemia (ALL), an ABL-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a TERF2::PDGFRB fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among PDGFRB-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for PDGFRB-rearranged ALL.

Indexed as

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsDasatinibDrug Resistance, NeoplasmImatinib MesylateOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptor, Platelet-Derived Growth Factor betaChildHumansMaleProtein Kinase InhibitorsAntibodies, BispecificblinatumomabDasatinibImatinib MesylateOncogene Proteins, FusionPDGFRB protein, humanProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaBlinatumomabMRD.PDGFRB-rearranged ALLTKIs

Identifiers

PMID40974379
PMCPMC12619738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.